Phaseline

Companies › Bharat Biotech International

Bharat Biotech International: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 4 Phase 2, 1 Phase 3; Infectious disease; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ROTAVAC 5D
Live attenuated rotavirus 116E vaccine
–Phase 3Rotavirus Infection of Children–
BBV87
Inactivated Chikungunya Virus Vaccine
–Phase 2Active Immunisation for Chikungunya Virus InfectionAug 2027
MTBVAC (BBV169)
Live attenuated Mycobacterium tuberculosis vaccine
MTBPhase 2Tuberculosis (TB); HIV I Infection–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06200844ROTAVAC 5DPhase 3Rotavirus Infection of ChildrenInfectious diseaseJan 2025
NCT06997367MTBVAC (BBV169)Phase 2Tuberculosis (TB)Infectious diseaseSep 2025
NCT07555392BBV87Phase 2Active Immunisation for Chikungunya Virus InfectionInfectious diseaseAug 2027
NCT05947890MTBVAC (BBV169)Phase 2HIV I InfectionInfectious diseaseNov 2027
NCT06272812MTBVAC (BBV169)Phase 2Tuberculosis (TB)Infectious diseaseDec 2028

Targets

MTB (1)

Companies with the same targets

–

Companies built like this

Sinovac Life Sciences Green Cross Bavarian Nordic Osivax Artcline

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.